Multidisciplinary treatment approaches have greatly improved the prognosis of patients with Ewing's sarcoma. Four- or five-drug combination chemotherapy regimens are combined with radiation and/or surgery for local control. Currently, in the Cooperative Ewing's Sancoma Study (CESS) trials, approximately 60% of the protocol patients with Ewing's sarcoma show a relapse-free 10-year survival. For improvement of local control, preoperative radiotherapy and/or brachytherapy may be helpful. The early detection of blood and/or bone marrow contamination by molecular diagnosis can lead to a new clinical staging system. A myeloablative regimen consisting of simultaneous total body irradiation and chemotherapy may improve the prognosis of patients with disseminated disease.
|Number of pages||5|
|Journal||Journal of Orthopaedic Science|
|Publication status||Published - Jan 1 1997|
- Ewing's sarcoma
ASJC Scopus subject areas
- Orthopedics and Sports Medicine